TherimuneX Overview
- Year Founded
-
2005
- Status
-
Out of Business
- Latest Deal Type
-
Out of Business
TherimuneX General Information
Description
Developer of inflammasome signaling platform designed to exploit the commercial applications of a new medical discovery. The company's platform relates to a new family of endogenous lipopeptides and their immune regulating properties leading to the development of a new therapeutic peptide, enabling doctors to treat and prevent infectious diseases including cancer and scleroderma.
Contact Information
Primary Industry
Biotechnology
Other Industries
Other Pharmaceuticals and Biotechnology
Primary Office
- 5110 Campus Drive
- Plymouth Meeting, PA 19462
- United States
+1 (610) 000-0000
TherimuneX Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Out of Business | 01-Jun-2018 | Completed | Out of Business | |||
| 3. Debt - General | Completed | Generating Revenue | ||||
| 2. Later Stage VC | 01-Nov-2011 | Completed | Generating Revenue | |||
| 1. Grant | 01-Jan-2009 | $636K | Completed | Startup |
TherimuneX Patents
TherimuneX Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20120238491-A1 | Immunologically active lipopeptides and methods for use thereof | Inactive | 10-Apr-2009 | 000000000 | |
| AU-2009240516-B2 | Peptidyl diacylglycerides | Inactive | 24-Apr-2008 | 000000000 | |
| AU-2009240516-A1 | Peptidyl diacylglycerides | Active | 24-Apr-2008 | 000000000 | |
| CA-2727973-A1 | Peptidyl diacylglycerides | Active | 24-Apr-2008 | 000000000 | |
| CA-2727973-C | Peptidyl diacylglycerides | Active | 24-Apr-2008 | A61K38/10 |